Literature DB >> 17357807

Branch retinal artery occlusion associated with compound heterozygous genotype for methylenetetrahydrofolate reductase.

Martin Heur1, Gregory S Kosmorsky, Neal S Peachey, Elisa Bala.   

Abstract

We present a case in which mfERG and OCT helped to make a diagnosis of an old BRAO in the setting of compound heterozygous MTHFR genotype. A 44-year-old woman presented for evaluation of a 10 month history of persistently cloudy vision OS. She had been worked up previously for MS versus BRAO, and she was on coumadin, folate, and multivitamin at the time of presentation. The patient has a fraternal twin sister who was diagnosed with MS. Dilated fundus examination OS showed subtle inferior optic atrophy with slight narrowing of the inferotemporal retinal artery, and HVF test revealed a superonasal depression OS. mfERG also showed superonasal depression OS. Retinal origin of the chief complaint was further confirmed by OCT, which showed thinning of the NFL in the corresponding region of the retina OS. Coagulopathy evaluation revealed C677T/A1298C compound heterozygous genotype for MTHFR, and plasma homocysteine level after 6 months of folate and multivitamin supplementation was 10 microM (reference range 4-10 microM). The patient was diagnosed with BRAO and maintained on coumadin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17357807     DOI: 10.1007/s10633-007-9051-3

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   1.854


  12 in total

Review 1.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  Folic acid improves arterial endothelial function in adults with hyperhomocystinemia.

Authors:  K S Woo; P Chook; Y I Lolin; J E Sanderson; C Metreweli; D S Celermajer
Journal:  J Am Coll Cardiol       Date:  1999-12       Impact factor: 24.094

Review 3.  Homocysteine and vascular disease.

Authors:  K S McCully
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

4.  Hyperhomocysteinemia: an independent risk factor for vascular disease.

Authors:  R Clarke; L Daly; K Robinson; E Naughten; S Cahalane; B Fowler; I Graham
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

5.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

6.  The role of hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with retinal artery occlusion.

Authors:  Martin Weger; Olaf Stanger; Hannes Deutschmann; Franz Josef Leitner; Wilfried Renner; Otto Schmut; Jürgen Semmelrock; Anton Haas
Journal:  Am J Ophthalmol       Date:  2002-07       Impact factor: 5.258

7.  Hyperhomocysteinemia in retinal artery and retinal vein occlusion.

Authors:  E M Wenzler; A J Rademakers; G H Boers; J R Cruysberg; C A Webers; A F Deutman
Journal:  Am J Ophthalmol       Date:  1993-02-15       Impact factor: 5.258

8.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

Authors:  M den Heijer; T Koster; H J Blom; G M Bos; E Briet; P H Reitsma; J P Vandenbroucke; F R Rosendaal
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

9.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.

Authors:  A M Engbersen; D G Franken; G H Boers; E M Stevens; F J Trijbels; H J Blom
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

10.  Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions.

Authors:  B O Choi; N K Kim; S H Kim; M S Kang; S Lee; J Y Ahn; O J Kim; S Kim; D Oh
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.